Connecticut consolidation finally over for Pfizer

Pfizer says the painful cutting at its R&D operations in Connecticut is finally over. And the budget ax evidently cut a little deeper than expected. The pharma giant told The Day that it now has 3,300 employees at its consolidated headquarters in Groton. Two years ago Pfizer outlined plans to chop 1,100 staffers, mostly scientists, in order to whittle down its R&D budget. That should have left 3,400 staffers. "There are no further planned reductions," Pfizer spokeswoman Lauren Starr tells The Day. "Groton is of central importance to the company." The company has a number of facilities up for sale in the wake of the consolidation. Story

 

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.